Oncocyte to Acquire Chronix Biomedical
The transaction includes proprietary IP and technology for blood-based immune therapy monitoring and for transplant rejection testing.
Read MorePosted by Melanie Hamilton-Basich | Feb 4, 2021 | Company News, Lung Cancer, Molecular Diagnostics, Transfusion & Transplantation Tests |
The transaction includes proprietary IP and technology for blood-based immune therapy monitoring and for transplant rejection testing.
Read MorePosted by Laurie Bonner | Jan 27, 2021 | Lung Cancer, Molecular Diagnostics |
Study to focus on using saliva in the analysis of cell-free circulating tumor DNA to accurately and noninvasively detect non-small cell lung cancer.
Read MorePosted by Laurie Bonner | Jan 13, 2021 | Cancer, Molecular Diagnostics |
Growth of RNA sequencing allows physicians and researchers to analyze a patient’s full genetic profile.
Read MorePosted by Melanie Hamilton-Basich | Nov 17, 2020 | Flow Cytometry, Lung Cancer |
The test validation trial resulted in CyPath Lung specificity of 88% and sensitivity of 82%, similar to far more invasive procedures currently used to diagnose lung cancer.
Read MorePosted by Laurie Bonner | Nov 4, 2020 | Covid 19, Immunoassay Reagents & test Kits |
Engineered recombinant antibodies offer advantages over serum-based controls.
Read More